77 related articles for article (PubMed ID: 27281312)
1. Intrinsic Subgroups or Individual Biomarkers for Predicting Outcome of Metastatic Breast Cancer?
Dowsett M
JAMA Oncol; 2016 Oct; 2(10):1269-1271. PubMed ID: 27281312
[No Abstract] [Full Text] [Related]
2. Is initially metastatic breast carcinoma different from recurrent metastatic breast carcinoma?
Dizdar O; Aksoy S; Altundag K
Ann Oncol; 2009 Jan; 20(1):189; author reply 189-90. PubMed ID: 18820244
[No Abstract] [Full Text] [Related]
3. Breast cancer survival and immunohistochemical similarities between primary and metastatic sites, as a surrogate marker for the cancer self-seeding.
Kurbel S; Dmitrovic B; Tomas I; Kristek J; Bozac M
Int J Biol Markers; 2012 Jul; 27(2):e167-8. PubMed ID: 22653743
[No Abstract] [Full Text] [Related]
4. Impact of breast cancer subtypes and patterns of metastasis on outcome.
Kast K; Link T; Friedrich K; Petzold A; Niedostatek A; Schoffer O; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Breast Cancer Res Treat; 2015 Apr; 150(3):621-9. PubMed ID: 25783184
[TBL] [Abstract][Full Text] [Related]
5. Significance of iodine symporter for prognosis of the disease course and efficacy of neoadjuvant chemotherapy in patients with breast cancer of luminal and basal subtypes.
Chekhun VF; Andriiv AV; Lukianova NY
Exp Oncol; 2017 Mar; 39(1):65-68. PubMed ID: 28361851
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of metastatic behaviour of breast cancer subtypes.
Savci-Heijink CD; Halfwerk H; Hooijer GK; Horlings HM; Wesseling J; van de Vijver MJ
Breast Cancer Res Treat; 2015 Apr; 150(3):547-57. PubMed ID: 25820592
[TBL] [Abstract][Full Text] [Related]
7. DEK: A novel early screening and prognostic marker for breast cancer.
Ying G; Wu Y
Mol Med Rep; 2015 Nov; 12(5):7491-5. PubMed ID: 26459608
[TBL] [Abstract][Full Text] [Related]
8. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
[TBL] [Abstract][Full Text] [Related]
9. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.
Fabi A; Moscetti L; Ciccarese M; Caramanti M; Salesi N; La Verde N; Russillo M; Generali D; Scandurra G; Vari S; Pacetti U; Cognetti F; Giannarelli D
Future Oncol; 2015; 11(3):431-8. PubMed ID: 25675124
[TBL] [Abstract][Full Text] [Related]
10. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
11. [Advances on breast cancer: a perspective].
Vera-Román JM
Med Clin (Barc); 2012 Sep; 139(7):293-4. PubMed ID: 22672964
[No Abstract] [Full Text] [Related]
12. Advanced breast cancers increasing in young women.
BMJ; 2013 Feb; 346():f1234. PubMed ID: 23447342
[No Abstract] [Full Text] [Related]
13. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.
Santa-Maria CA; Gradishar WJ
JAMA Oncol; 2015 Jul; 1(4):528-34; quiz 549. PubMed ID: 26181262
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor Cells.
Paoletti C; Hayes DF
Adv Exp Med Biol; 2016; 882():235-58. PubMed ID: 26987538
[TBL] [Abstract][Full Text] [Related]
15. Sperm-associated antigen 9 overexpression correlates with poor prognosis and insensitive to Taxol treatment in breast cancer.
Yang C; Shen B; Zhang J; Zhang Q
Biomarkers; 2016; 21(1):62-7. PubMed ID: 26631164
[TBL] [Abstract][Full Text] [Related]
16. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
17. Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer.
Wu J; Zhang S; Shan J; Hu Z; Liu X; Chen L; Ren X; Yao L; Sheng H; Li L; Ann D; Yen Y; Wang J; Wang X
Cancer Lett; 2016 Jul; 376(2):284-92. PubMed ID: 27063096
[TBL] [Abstract][Full Text] [Related]
18. Pro-metastatic tumor-stroma interactions in breast cancer.
Gangadhara S; Barrett-Lee P; Nicholson RI; Hiscox S
Future Oncol; 2012 Nov; 8(11):1427-42. PubMed ID: 23148616
[TBL] [Abstract][Full Text] [Related]
19. Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification.
Aleskandarany MA; Soria D; Green AR; Nolan C; Diez-Rodriguez M; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jun; 151(2):325-33. PubMed ID: 25953687
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
